Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography. The research hypothesis is that nasal high-flow would increase cardiac output in patients with pulmonary hypertension. The concomitant echocardiography will allow to describe its sensibility to detect cardiovascular consequences of nasal high-flow.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nasal high-flow 30 L/min and then 50 L/min | Experimental | The patient will be placed successively under nasal high-flow 30 L/min during 20 min and then 50 L/min during 20 min. |
|
| Nasal high-flow 50 L/min and then 30 L/min | Experimental | The patient will be placed successively under nasal high-flow 50 L/min during 20 min and then 30 L/min during 20 min. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nasal high-flow | Device | Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac output | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| Measure | Description | Time Frame |
|---|---|---|
| cardiac output | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| cardiac output | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air |
Not provided
Inclusion Criteria:
- patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elise ARTAUD-MACARI, MD | Contact | +33 2 32 88 59 92 | elise.artaud-macari@chu-rouen.fr | |
| Maryline LEFORT, RT | Contact | +33 2 32 88 59 92 | mlefort@adir-hautenormandie.com |
| Name | Affiliation | Role |
|---|---|---|
| Elise ARTAUD-MACARI, MD | ADIR Association | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ROUEN university hospital | Recruiting | Rouen | 76000 | France |
Not provided
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
Not provided
Not provided
All patients will be randomly allocated into two groups using the block randomization technique (4 or 8 according to an equiprobable distribution) in a 1:1 ratio. The randomisation will be performed at the begining of the catheterization procedure. In the first arm, the patient will successively receive 30 L/min then 50 L/min of room air. In the second arm, the patient will successively receive 50 L/min then 30 L/min of room air.
Not provided
Not provided
Not provided
Not provided
| During the intervention, at isotime |
| Right atrial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| Right atrial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| Right atrial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| systolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| diastolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| diastolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| diastolic pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| mean pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| mean pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| mean pulmonary arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| capillary wedge pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| capillary wedge pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| capillary wedge pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| pulmonary vascular resistance | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| pulmonary vascular resistance | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| pulmonary vascular resistance | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| central venous oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| central venous oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| central venous oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| heart rate | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| heart rate | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| heart rate | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| systolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| diastolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| diastolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| diastolic arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| mean arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| mean arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| mean arterial pressure | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| systolic ejection volume | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic ejection volume | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| systolic ejection volume | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| respiratory rate | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| respiratory rate | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| respiratory rate | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| pulse oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 50L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| pulse oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air | During the intervention, at isotime |
| pulse oxygen saturation | Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min | During the intervention, at isotime |
| Consequences of nasal high-flow 50 and 30 L/min FiO2 21% on echocardiographic parameters. | Cardiac output, inferior vena cava diameter and collapsibiliy, systolic pulmoanry arterial pressure, tricuspid regurgitation velocity,tricuspid annular plane systolic excursion, right ventricule strain, tricuspid S wave, right on left ventricular telediastolic surface ratio, left ventricular ejection fraction, mitral doppler, mitral S wave, respiratory variability of E mitral wave | During the intervention, at isotime |
| systolic pulmonary arterial pressure measured by catheterization and echocardiography. | Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography. | During the intervention, at isotime |
| capillary wedge pressure measured by catheterization and echocardiography. | Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography. | During the intervention, at isotime |
| right atrial pressure measured by catheterization and echocardiography. | Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography. | During the intervention, at isotime |
| cardiac output measured by catheterization and echocardiography. | Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography. | During the intervention, at isotime |
| D002318 |
| Cardiovascular Diseases |